MedStar Authors catalog › Details for: Biologics and Cardiovascular Disease.
Normal view MARC view ISBD view

Biologics and Cardiovascular Disease.

by Van Taunay, John S; Lipinski, Michael J.
Citation: Journal of Cardiovascular Pharmacology. 72(2):77-85, 2018 08..Journal: Journal of cardiovascular pharmacology.Published: 2018ISSN: 0160-2446.Full author list: Van Taunay JS; Albelda MT; Frias JC; Lipinski MJ.UI/PMID: 29738370.Subject(s): Animals | *Anti-Inflammatory Agents/ad [Administration & Dosage] | Anti-Inflammatory Agents/ae [Adverse Effects] | *Biological Products/ad [Administration & Dosage] | Biological Products/ae [Adverse Effects] | Cardiotoxicity | *Cardiovascular Agents/ad [Administration & Dosage] | Cardiovascular Agents/ae [Adverse Effects] | *Cardiovascular Diseases/dt [Drug Therapy] | Cardiovascular Diseases/ge [Genetics] | Cardiovascular Diseases/im [Immunology] | Cardiovascular Diseases/me [Metabolism] | *Cytokines/ai [Antagonists & Inhibitors] | Cytokines/im [Immunology] | Cytokines/me [Metabolism] | Humans | *Inflammation Mediators/ai [Antagonists & Inhibitors] | Inflammation Mediators/im [Immunology] | Inflammation Mediators/me [Metabolism] | Liposomes | Proprotein Convertase 9/ge [Genetics] | RNA, Small Interfering/tu [Therapeutic Use] | RNAi Therapeutics/mt [Methods] | Signal Transduction/de [Drug Effects] | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1097/FJC.0000000000000595 (Click here) Abbreviated citation: J Cardiovasc Pharmacol. 72(2):77-85, 2018 08.Local Holdings: Available online from MWHC library: 1996 - present.Abstract: The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations. Atherosclerosis, myocardial infarction, and heart failure have been closely linked to the inflammatory response. Accordingly, cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 have been targeted. Non-inflammatory mediators, such as proprotein convertase subtilisin kexin type 9 (PCSK9), have been selected for therapeutic intervention as well. Furthermore, RNA interference (RNAi) therapy has emerged and may serve as another targeted therapeutic mechanism. Herein, we will review the history, obstacles, and advances in utilizing biologic therapy for CVD.

Powered by Koha